Oxigene Inc. will cut 11 jobs, reduce its footprint, kill plans for a Phase III thyroid cancer study and end a Phase II lung cancer study as it focuses on sponsored early-stage clinical programs.
The moves, which will leave the South San Francisco biotech company (NASDAQ: OXGN) with five full-time employees, will slash about $2 million in annual expenses.
No comments:
Post a Comment